title: Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
abstract: OBJECTIVE
  We aimed to evaluate the efficacy and tolerability of hepatic arterial infusion chemotherapy (HAIC) using cisplatin as an alternative to sorafenib for the treatment of hepatocellular carcinoma (HCC) patients who had not responded to transarterial chemoembolization (TACE).
  
  
  METHODS
  Medical records of 127 consecutive HCC patients without extrahepatic metastasis (cisplatin, n = 44; sorafenib, n = 83) who had not responded to prior TACE at four institutions were retrospectively reviewed. An inverse probability of treatment weighting using propensity scoring was used to adjust for the selection bias.
  
  
  RESULTS
  Severe adverse events accounting for treatment discontinuation occurred in 2.3% of the patients in the cisplatin group and 32.5% of those in the sorafenib group. The median overall survival (OS) period was 11.2 months (95% CI 4.8-17.7) in the cisplatin group and 10.2 months (95% CI 8.8-11.5) in the sorafenib group, respectively. After an inverse probability of treatment weighting adjustment, the survival outcome of the HAIC treatment group was not inferior to that of the sorafenib treatment group (hazard ratio 0.758; 95% CI 0.471-1.219, P = 0.253).
  
  
  CONCLUSIONS
  HAIC with cisplatin can be an alternative treatment for the selection of HCC patients who have not responded to prior TACE and cannot tolerate sorafenib.
authors.affiliation: Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
authors.forename: Masaaki
authors.initials: M
authors.lastname: Kondo
authors.forename: Manabu
authors.initials: M
authors.lastname: Morimoto
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Ishii
authors.forename: Akito
authors.initials: A
authors.lastname: Nozaki
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Fukuda
authors.forename: Kazushi
authors.initials: K
authors.lastname: Numata
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Shinichi
authors.initials: S
authors.lastname: Ohkawa
authors.forename: Hisashi
authors.initials: H
authors.lastname: Hidaka
authors.forename: Takahide
authors.initials: T
authors.lastname: Nakazawa
authors.forename: Akitaka
authors.initials: A
authors.lastname: Shibuya
authors.forename: Chiaki
authors.initials: C
authors.lastname: Okuse
authors.forename: Michihiro
authors.initials: M
authors.lastname: Suzuki
authors.forename: Kentaro
authors.initials: K
authors.lastname: Sakamaki
authors.forename: Satoshi
authors.initials: S
authors.lastname: Morita
authors.forename: Shin
authors.initials: S
authors.lastname: Maeda
authors.forename: Katsuaki
authors.initials: K
authors.lastname: Tanaka
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000628:therapy; D016461:Chemoembolization, Therapeutic; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation / Q000379:methods; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D057216:Propensity Score; D012189:Retrospective Studies; D000077157:Sorafenib; D016019:Survival Analysis; D017211:Treatment Failure
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; D002945:Cisplatin
keywords: cisplatin; hepatocellular carcinoma; propensity score; sorafenib